Home>>Signaling Pathways>> GPCR/G protein>> CCK1 Receptors>>Sincalide (CCK-8)

Sincalide (CCK-8) (Synonyms: CCK-8S, Cholecystokinin (26-33), SQ 19,844, Sincalide)

Catalog No.GC32749

Sincalide(CCK-8) is a minor bioactive segment of CCK

Products are for research use only. Not for human use. We do not sell to patients.

Sincalide (CCK-8) Chemical Structure

Cas No.: 25126-32-3

Size Price Stock Qty
1mg
$101.00
In stock
5mg
$304.00
In stock
10mg
$450.00
In stock
25mg
$873.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Sincalide(CCK-8) is a minor bioactive segment of CCK that retains most of the biological activities of CCK and is widely used to study CCK functions[1]. Sincalide is a rapid-acting, synthetic analog of cholecystokinin for intravenous use in postevacuation cholecystography, and has a variety of effects as a novel cardiovascular hormone[2,3].

Sincalide protects H9c2 cardiomyoblasts from Ang II-induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol-3 kinase/protein kinase B (PI3K/Akt) signaling pathway[1]. Sincalide can protect human retinal pigment epithelial cells against apoptosis induced by peroxynitrite[4]. Sincalide dose-dependently inhibited METH-induced cytotoxic effect by activating the CCK2 receptor subtype in PC12 cells and CCK2 receptor stable transfected-HEK293 cells[5]

Sincalide can alleviate fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model[2]. Sincalide decreased RPE cells apoptosis partly induced by ONOO- in Sprague-Dawley rats and is a potential drug for therapy of diabetic retinopathy[6]. Intramuscular injection of sincalide (0.07μg/kg) induced remarkable contractions of the gallbladder in vivo, and the contraction was nearly abolished by premedication of atropine sulfate (0.015 mg/kg)[7]

References:
[1]. Wang C, Yu H, et al. Protective effect of cholecystokinin octapeptide on angiotensin II-induced apoptosis in H9c2 cardiomyoblast cells. J Cell Biochem. 2020;121(7):3560-3569.
[2]. Wang C, Zhang C, et al. Cholecystokinin octapeptide reduces myocardial fibrosis and improves cardiac remodeling in post myocardial infarction rats. Int J Biochem Cell Biol. 2020;125:105793.
[3]. Maher KA. Kinevac (sincalide for injection)/Squibb Diagnostics. Gastroenterol Nurs. 1991;14(2):98-100.
[4]. Liu Y, Zhang Y, et al. Cholecystokinin octapeptide antagonizes apoptosis in human retinal pigment epithelial cells. Neural Regen Res. 2014;9(14):1402-1408.
[5]. Wen D, An M, et al. Cholecystokinin-8 inhibits methamphetamine-induced neurotoxicity via an anti-oxidative stress pathway. Neurotoxicology. 2016;57:31-38.
[6]. Hao LN, Wang M, et al. Control of peroxyntrite-induced production of inducible nitric oxide synthase isoforms and antagonism of cholecystokinin octapeptide -8 in retinal pigment epithelial cells in vivo. Int J Ophthalmol. 2011;4(6):605-610.
[7]. Takahashi T, Yamamura T, et al. Effects of cholecystokinin-octapeptide on the human gallbladder both in vivo and in vitro. Gastroenterol Jpn. 1986;21(1):49-54.

Reviews

Review for Sincalide (CCK-8)

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sincalide (CCK-8)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.